TMCnet News
MITRE Names Dr. John Noseworthy to Board of TrusteesMITRE's Board of Trustees has elected Dr. John Noseworthy, president and CEO emeritus of the Mayo Clinic, to serve on the board for a three-year term. This additional board seat will support the company's growth in healthcare innovation and pandemic response engagements. MITRE operates the Health Federally Funded R&D Center for the Centers for Medicare & Medicaid Services and manages the COVID-19 Healthcare Coalition, an industry group of more than 800 companies co-chaired by the Mayo Clinic and MITRE. "We are pleased to welcome Dr. Noseworthy to our Board of Trustees," said Jason Providakes, MITRE president and CEO. "His strategic insight and vast healthcare leadership experience support our continued growth efforts in the healthcare sector, especially our critical work surrounding the COVID-19 crisis, as well as planning for future pandemics with the creation of a national pandemic platform."
Prior to his appointment as CEO, Noseworthy served as professor and chair of the Mayo Clinic's Department of Neurology, medical director of the Department of Development and editor-in-chief of the journal Neurology. A specialist in multiple sclerosis, he designed and conducted controlled clinical trials over two decades. His books include a three-volume textbook "Neurological Therapeutics: Principles and Practice." Noseworthy holds a medical degree from Dalhousie University in New Brunswick, Canada, where he began his neurology training. He is a Fellow in Neurology with the Royal College of Physicians and Surgeons of Canada. About MITRE MITRE's mission-driven teams are dedicated to solving problems for a safer world. Through our public-private partnerships and federally funded R&D centers, we work across government and in partnership with industry to tackle challenges to the safety, stability, and well-being of our nation. View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005486/en/ |